1. Market Research
  2. > Lux Biosciences, Inc. - Product Pipeline Review - 2013

Lux Biosciences, Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 34 pages

Lux Biosciences, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Lux Biosciences, Inc. - Product Pipeline Review - 2013” provides data on the Lux Biosciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Lux Biosciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Lux Biosciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Lux Biosciences, Inc. - Brief Lux Biosciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lux Biosciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lux Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lux Biosciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Lux Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Lux Biosciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lux Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Lux Biosciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Lux Biosciences, Inc. and identify potential opportunities in those areas.

Table Of Contents

Lux Biosciences, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Lux Biosciences, Inc. Snapshot 5
Lux Biosciences, Inc. Overview 5
Key Information 5
Key Facts 5
Lux Biosciences, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Lux Biosciences, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Lux Biosciences, Inc. - Pipeline Products Glance 12
Lux Biosciences, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Lux Biosciences, Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Lux Biosciences, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Lux Biosciences, Inc. - Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
Lux Biosciences, Inc. - Drug Profiles 17
voclosporin 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
LX-214 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
LX-212 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
LX-213 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Lux Biosciences, Inc. - Pipeline Analysis 22
Lux Biosciences, Inc. - Pipeline Products by Therapeutic Class 22
Lux Biosciences, Inc. - Pipeline Products by Target 24
Lux Biosciences, Inc. - Pipeline Products by Route of Administration 25
Lux Biosciences, Inc. - Pipeline Products by Molecule Type 26
Lux Biosciences, Inc. - Pipeline Products by Mechanism of Action 27
Lux Biosciences, Inc. - Recent Pipeline Updates 28
Lux Biosciences, Inc. - Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34



List of Tables

Lux Biosciences, Inc., Key Information 5
Lux Biosciences, Inc., Key Facts 5
Lux Biosciences, Inc. - Pipeline by Indication, 2013 7
Lux Biosciences, Inc. - Pipeline by Stage of Development, 2013 8
Lux Biosciences, Inc. - Monotherapy Products in Pipeline, 2013 9
Lux Biosciences, Inc. - Partnered Products in Pipeline, 2013 10
Lux Biosciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2013 11
Lux Biosciences, Inc. - Phase III, 2013 12
Lux Biosciences, Inc. - Phase I, 2013 13
Lux Biosciences, Inc. - Preclinical, 2013 14
Lux Biosciences, Inc. - Discovery, 2013 15
Lux Biosciences, Inc. - Unknown, 2013 16
Lux Biosciences, Inc. - Pipeline by Therapeutic Class, 2013 23
Lux Biosciences, Inc. - Pipeline by Target, 2013 24
Lux Biosciences, Inc. - Pipeline by Route of Administration, 2013 25
Lux Biosciences, Inc. - Pipeline by Molecule Type, 2013 26
Lux Biosciences, Inc. - Pipeline Products by Mechanism of Action, 2013 27
Lux Biosciences, Inc. - Recent Pipeline Updates, 2013 28



List of Figures

Lux Biosciences, Inc. - Pipeline by Top 10 Indication, 2013 7
Lux Biosciences, Inc. - Pipeline by Stage of Development, 2013 8
Lux Biosciences, Inc. - Monotherapy Products in Pipeline, 2013 9
Lux Biosciences, Inc. - Partnered Products in Pipeline, 2013 10
Lux Biosciences, Inc. - Pipeline by Top 10 Therapeutic Class, 2013 22
Lux Biosciences, Inc. - Pipeline by Top 10 Target, 2013 24
Lux Biosciences, Inc. - Pipeline by Top 10 Route of Administration, 2013 25
Lux Biosciences, Inc. - Pipeline by Top 10 Molecule Type, 2013 26
Lux Biosciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2013 27



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.